The end of a project and the start of a new one can be a significant turning point for individuals and organisations alike. It represents a chance to reflect, renew, and anticipate a fresh horizon. That’s why last week—with the completion of Innovative Medicines Initiative-funded project EU-PEARL and the kick-off of Horizon Europe-funded project FIBROTARGET—meant so much for Teamit Research.
In 2018, when Teamit Research first helped draft the proposal call for EU-PEARL, we could not have foreseen the 200+ multistakeholder-involved closing event in Brussels last week and all the achievements made thus far. We only reiterated how important strategic project management and communications would serve in day-to-day interactions with project partners. Yet, as we reached the final stretch of the 3.5-year project, it became quite clear. An EU-funded initiative could very much deliver the real-world impact it seeks if it welcomed the support of a multidisciplinary team bred in three primary areas: expertise, versatility, and tenacity.
In the case of EU-PEARL, whose main aim was to advance collaborative platform trials to accelerate the development of medicines, we at Teamit Research implemented the following actions to reinforce the consortium contributions to health and ensure a higher likelihood of result uptake even after the project’s final date, such as:
- Creating an easy-to-follow, resource-rich website that would share the project’s results for years to come.
- Organising an open closing event with insightful roundtables about collaborative and patient-centric platform trials in Brussels.
- Disseminating and promoting the innovative, generic framework and set of tools created by the EU-PEARL consortium for collaborative platform trials to take place.
- Highlighting and acknowledging the benefits and learnings of public-private collaborations, by which all stakeholders learn, expand their networks, and contribute to more impactful results.
Interestingly, this project may have now finished, but its legacy continues.
We say this with pride and excitement because we now inherit learnings gained from EU-PEARL to apply in our newest project FIBROTARGET.
With active roles in both the coordination of the project and its communications and dissemination, Teamit Research will have to commit to excellence once again to help this consortium accomplish its final objective—to advance in the diagnosis and availability of (immune)therapies for inflammatory bowel disease. A 5-year undertaking, FIBROTARGET will be the next challenge for Teamit Research to face… but it most certainly won’t be the last.
